ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis
NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD
Overall ORGO gets a fundamental rating of 5 out of 10. We evaluated ORGO against 551 industry peers in the Biotechnology industry. Both the profitability and the financial health of ORGO get a neutral evaluation. Nothing too spectacular is happening here. ORGO has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ORGO was profitable.
ORGO had a positive operating cash flow in the past year.
ORGO had positive earnings in 4 of the past 5 years.
In the past 5 years ORGO always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -4.37%, ORGO belongs to the top of the industry, outperforming 87.84% of the companies in the same industry.
ORGO has a Return On Equity of -5.55%. This is amongst the best in the industry. ORGO outperforms 90.02% of its industry peers.
ORGO's Return On Invested Capital of 1.02% is amongst the best of the industry. ORGO outperforms 91.83% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ORGO is significantly below the industry average of 14.79%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROIC | 1.02% |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
1.3 Margins
ORGO's Operating Margin of 1.13% is amongst the best of the industry. ORGO outperforms 92.01% of its industry peers.
ORGO's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 75.85%, ORGO belongs to the best of the industry, outperforming 83.67% of the companies in the same industry.
ORGO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% |
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
2. Health
2.1 Basic Checks
ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ORGO has less shares outstanding
Compared to 5 years ago, ORGO has more shares outstanding
Compared to 1 year ago, ORGO has an improved debt to assets ratio.
2.2 Solvency
ORGO has an Altman-Z score of 4.83. This indicates that ORGO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 4.83, ORGO is doing good in the industry, outperforming 76.41% of the companies in the same industry.
ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ORGO's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. ORGO outperforms 46.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.83 |
ROIC/WACC0.09
WACC11.18%
2.3 Liquidity
A Current Ratio of 4.12 indicates that ORGO has no problem at all paying its short term obligations.
ORGO has a Current ratio (4.12) which is in line with its industry peers.
A Quick Ratio of 3.67 indicates that ORGO has no problem at all paying its short term obligations.
With a Quick ratio value of 3.67, ORGO perfoms like the industry average, outperforming 44.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 125.00% over the past year.
ORGO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -37.90% yearly.
ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 5.36%.
The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
3.2 Future
The Earnings Per Share is expected to grow by 24.29% on average over the next years. This is a very strong growth
ORGO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.81% yearly.
EPS Next Y-118%
EPS Next 2Y8.17%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue Next Year5.05%
Revenue Next 2Y6.81%
Revenue Next 3Y6.81%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ORGO is valuated quite expensively with a Price/Earnings ratio of 50.06.
91.47% of the companies in the same industry are more expensive than ORGO, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.03. ORGO is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 22.65, which indicates a rather expensive current valuation of ORGO.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 91.83% of the companies listed in the same industry.
ORGO is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.28, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.06 | ||
| Fwd PE | 22.65 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 94.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.7 |
4.3 Compensation for Growth
ORGO has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ORGO's earnings are expected to grow with 24.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.17%
EPS Next 3Y24.29%
5. Dividend
5.1 Amount
No dividends for ORGO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ORGO (8/6/2025, 1:19:58 PM)
4.505
-0.03 (-0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners51.78%
Inst Owner Change4.16%
Ins Owners31.29%
Ins Owner Change1.49%
Market Cap571.46M
Analysts84.44
Price Target7.14 (58.49%)
Short Float %14.38%
Short Ratio10.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)248.79%
Min EPS beat(2)-73%
Max EPS beat(2)570.59%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-6.36%
Max Revenue beat(2)13.3%
Revenue beat(4)3
Avg Revenue beat(4)3.87%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)4
Avg Revenue beat(8)0.9%
Revenue beat(12)5
Avg Revenue beat(12)0.29%
Revenue beat(16)7
Avg Revenue beat(16)0.94%
PT rev (1m)12%
PT rev (3m)16.67%
EPS NQ rev (1m)-13.34%
EPS NQ rev (3m)-466.7%
EPS NY rev (1m)-146.15%
EPS NY rev (3m)-180%
Revenue NQ rev (1m)2.21%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)0.86%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.06 | ||
| Fwd PE | 22.65 | ||
| P/S | 1.25 | ||
| P/FCF | N/A | ||
| P/OCF | 128.85 | ||
| P/B | 1.55 | ||
| P/tB | 1.74 | ||
| EV/EBITDA | 20.7 |
EPS(TTM)0.09
EY2%
EPS(NY)0.2
Fwd EY4.42%
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)0.03
OCFY0.78%
SpS3.62
BVpS2.9
TBVpS2.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.37% | ||
| ROE | -5.55% | ||
| ROCE | 1.29% | ||
| ROIC | 1.02% | ||
| ROICexc | 1.4% | ||
| ROICexgc | 1.63% | ||
| OM | 1.13% | ||
| PM (TTM) | N/A | ||
| GM | 75.85% | ||
| FCFM | N/A |
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 65.96% | ||
| Cap/Sales | 2.49% | ||
| Interest Coverage | 1.44 | ||
| Cash Conversion | 19.68% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.67 | ||
| Altman-Z | 4.83 |
F-Score6
WACC11.18%
ROIC/WACC0.09
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-118%
EPS Next 2Y8.17%
EPS Next 3Y24.29%
EPS Next 5YN/A
Revenue 1Y (TTM)5.36%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year5.05%
Revenue Next 2Y6.81%
Revenue Next 3Y6.81%
Revenue Next 5YN/A
EBIT growth 1Y-59.06%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year510.28%
EBIT Next 3Y111.89%
EBIT Next 5YN/A
FCF growth 1Y57.36%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-75.86%
OCF growth 3Y-38.8%
OCF growth 5YN/A